MAPK14 (Mitogen-Activated Protein Kinase 14), also known as p38α or CSBP (CSAID-binding protein), is a serine/threonine kinase belonging to the MAPK family. As one of four p38 MAPK isoforms (α, β, γ, δ), p38α is the most widely expressed and studied, with critical roles in cellular stress responses, inflammation, and neuronal function. The gene is located on chromosome 6p21.3 and encodes a 360-amino acid protein that is activated by cellular stress, inflammatory cytokines, and growth factors. MAPK14 is catalogued as NCBI Gene ID 5600 and OMIM 600289.
| p38α Mitogen-Activated Protein Kinase |
|---|
| Gene Symbol | MAPK14 |
| Alternative Names | p38α, CSBP, RK, SAPK2A |
| Full Name | Mitogen-Activated Protein Kinase 14 |
| Chromosome | 6p21.3 |
| NCBI Gene ID | [5600](https://www.ncbi.nlm.nih.gov/gene/5600) |
| OMIM | 600289 |
| Ensembl ID | ENSG00000166401 |
| UniProt ID | [Q16539](https://www.uniprot.org/uniprot/Q16539) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis |
MAPK14 is a serine/threonine kinase with a characteristic kinase domain that undergoes dual phosphorylation at Thr180 and Tyr182 for activation. The protein contains:
- N-terminal regulatory domain: Interactions with upstream kinases and substrates
- Kinase domain (aa 35-322): Catalytic activity, ATP binding
- C-terminal region: Docking interactions, localization signals
The active form requires both Thr180 and Tyr182 phosphorylation by upstream MAP kinase kinases (MKK3, MKK4, and MKK6).
MAPK14 is activated by diverse stimuli:
Cellular Stress:
- Oxidative stress (ROS, H2O2)
- UV radiation
- Osmotic stress
- Ischemia/hypoxia
Inflammatory Cytokines:
- TNF-α, IL-1β, IL-6
- TGF-β
- Interferons
Growth Factors:
The canonical MAPK14 cascade:
Cellular stress/inflammatory signals
↓
MKK3/MKK6 (MAP2K)
↓
MAPK14 (p38α) [Thr180/Tyr182 phosphorylation]
↓
Downstream substrates (transcription factors, kinases, cytoskeletal proteins)
↓
Cellular responses (inflammation, apoptosis, differentiation)
MAPK14 is a central driver of neuroinflammation in AD:
Microglial Activation:
- p38 MAPK is rapidly activated in microglia surrounding amyloid plaques
- Drives production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Promotes cyclooxygenase-2 (COX-2) and iNOS expression
- Creates chronic inflammatory microenvironment
Cytokine Cascade:
- TNF-α and IL-1β further activate p38 in neighboring cells
- Amplifies neuroinflammation in a feed-forward manner
- Leads to progressive neuronal dysfunction
Therapeutic Implications:
- p38 inhibition reduces microglial activation
- Decreases pro-inflammatory cytokine production
- Attenuates synaptic dysfunction in AD models
MAPK14 directly influences amyloid-beta metabolism:
APP Processing:
- p38 MAPK regulates β-secretase (BACE1) expression
- Affects γ-secretase activity indirectly
- Impacts amyloid precursor protein (APP) trafficking
Aβ Toxicity:
- p38 activation mediates Aβ-induced neuronal death
- Regulates Aβ-induced oxidative stress
- Controls inflammatory response to Aβ
Therapeutic Targeting:
- p38 inhibitors reduce amyloid burden in animal models
- May enhance Aβ clearance mechanisms
MAPK14 contributes to tau pathology through multiple mechanisms:
Direct Phosphorylation:
- p38α can phosphorylate tau at multiple sites
-增强 tau aggregation propensity
- Promotes NFT formation
Kinase Activation:
- Activates other tau kinases (GSK-3β, CDK5)
- Creates synergistic phosphorylation pattern
Implications for Therapy:
- Dual targeting of p38 and tau kinases may be beneficial
p38 MAPK mediates Aβ-induced synaptic impairment:
- Reduces synaptic plasticity markers
- Impairs LTP (long-term potentiation)
- Contributes to memory deficits
- Affects AMPA receptor trafficking
Inhibition of p38 restores synaptic function in AD models, highlighting its role in cognitive decline.
In PD, MAPK14 drives neuroinflammation in the substantia nigra:
- Activated microglia express elevated p38
- Contributes to dopaminergic neuron death
- Cytokine-mediated toxicity amplifies pathology
p38 MAPK affects α-synuclein:
- Regulates α-synuclein phosphorylation at Ser129
- Influences aggregation propensity
- Controls inflammatory response to α-synuclein aggregates
p38 contributes to mitochondrial impairment in PD:
- Mediates toxin-induced mitochondrial damage
- Regulates apoptotic pathways
- Contributes to energy failure
p38 inhibitors show promise in PD models:
- Reduce microglial activation
- Protect dopaminergic neurons
- Improve behavioral outcomes
MAPK14 is central to microglial inflammatory responses:
Activation Cascade:
- Pattern recognition receptors (TLRs) detect pathogens/damage
- Signaling cascades activate MKK3/6
- p38 MAPK translocates to nucleus
- Transcription factors (AP-1, CREB) activated
- Pro-inflammatory genes expressed
Cytokine Production:
- TNF-α, IL-1β, IL-6, IL-12
- Chemokines (MCP-1, MIP-1α)
- Prostaglandins via COX-2
p38 MAPK regulates astrocyte responses:
- Controls inflammatory mediator release
- Affects astrocyte reactivity
- Modulates metabolic support to neurons
p38 activation in neurons triggers:
- Apoptotic pathways
- Oxidative stress
- Excitotoxicity
- Calcium dysregulation
MAPK14 is activated by:
MAP2Ks:
- MKK3 (specific for p38)
- MKK4 (also activates JNK)
- MKK6 (specific for p38)
MAP3Ks:
p38 MAPK phosphorylates numerous substrates:
Transcription Factors:
- ATF2, c-Fos, c-Jun
- CREB, MEF2
- p53, NF-κB
Kinases:
- MSK1/2, MNK1/2
- PRAK (MAPKAPK3)
- MK2 (MAPKAPK2)
Cytoskeletal Proteins:
- Tau, MAPs
- Actin regulators
Several p38 MAPK inhibitors have been developed:
Clinical Candidates:
- Losmapimod (GW856553)
- PH-797804
- VX-745, VX-702
Challenges:
- CNS penetration limited
- Peripheral side effects
- Limited efficacy in chronic diseases
For Neurodegeneration:
- Brain-penetrant inhibitors needed
- Disease-modifying potential
- Combination approaches
p38 activation markers:
- Phospho-p38 in CSF
- Downstream cytokines (IL-1β, TNF-α)
- Microglial activation imaging
MAPK14 is expressed in:
- Neurons (high in hippocampus, cortex)
- Microglia (constitutively low, activation-induced)
- Astrocytes Oligodendrocytes
- Cytoplasmic (inactive)
- Nuclear (active, after stimulation)
- Mitochondrial (in stress responses)
p38 activity is controlled by:
- Phosphorylation (activation/inactivation)
- Phosphatases (PP2C, MKP)
- Scaffold proteins
- Subcellular localization
| Disease |
Role |
Evidence |
| Alzheimer's Disease |
Neuroinflammation, tau phosphorylation, Aβ toxicity |
Strong |
| Parkinson's Disease |
Neuroinflammation, α-syn pathology |
Moderate-Strong |
| Multiple Sclerosis |
Demyelination, inflammation |
Strong |
| Amyotrophic Lateral Sclerosis |
Motor neuron inflammation |
Moderate |
| Stroke |
Ischemic injury, inflammation |
Strong |
- p38 MAPK in Alzheimer's disease: from molecular mechanisms to therapeutic targeting (2019) — Journal of Neurochemistry
- p38 MAPK signaling in neuroinflammation: from mechanisms to therapy (2020) — Frontiers in Cellular Neuroscience
- Microglial p38 MAPK in neurodegenerative diseases (2021) — Journal of Neuroscience Research
- p38 MAPK in synaptic plasticity and memory (2020) — Learning & Memory
- p38 MAPK and tau pathology in Alzheimer's disease (2021) — Progress in Neuropsychopharmacology
- p38 MAPK inhibitors for neurodegenerative diseases (2022) — Pharmacological Research
- p38 MAPK in Parkinson's disease (2020) — Journal of Neural Transmission
- Astrocyte p38 MAPK in neuroinflammation (2021) — Glia
- p38 MAPK and amyloid-beta metabolism (2020) — Journal of Alzheimer's Disease
- Novel p38 MAPK inhibitors for Alzheimer's disease (2023) — Journal of Medicinal Chemistry
- Avraham R, Yarden Y, Regulation of MAP kinase signaling (2022)
- Roskoski R, RAF protein-serine/threonine kinases (2020)
- Keshet Y, Seger R, The MAP kinase signaling cascades (2021)
- Kim EK, Choi EJ, Pathological roles of MAPK pathways (2020)
- Downward J, Targeting RAF kinases (2023)
- Liu F et al., Targeting ERK, AKT, PKC in neurodegeneration (2022)
- Yue J, López JM, MAPK signaling in apoptosis (2021)
- Krishna M, Narang H, Complexity of MAPKs (2020)
- Correa M et al., p38 MAPK in Alzheimer's disease (2019)
- Zhang Y et al., p38 MAPK in neuroinflammation (2020)
- Liu M et al., Microglial p38 MAPK (2021)
- Zhang W et al., p38 MAPK in synaptic plasticity (2020)
- Wang J et al., p38 MAPK and tau pathology (2021)
- Kim S et al., p38 MAPK inhibitors (2022)
- Chen Y et al., p38 MAPK in neuronal development (2021)
- Li R et al., Oxidative stress activates p38 (2021)
- Park J et al., Novel p38 inhibitors (2023)
- Wang Y et al., p38 MAPK in Parkinson's disease (2020)
- Liu X et al., Astrocyte p38 MAPK (2021)
- Tan J et al., p38 MAPK and amyloid-beta metabolism (2020)